Search

Displaying results 4411 - 4420 of 9895 in total
  1. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV. … In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend ledipasvir as a first line

  2. Drug

    ATL1102

    go.drugbank.com/drugs/DB04997
    Investigational

    ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.

  3. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … [A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness.

  4. Drug

    Technetium Tc-99m tilmanocept

    go.drugbank.com/drugs/DB09266
    Approved

    Due to its relatively small molecular weight and small molecular diameter of 7 nm [A32168], technetium Tc-99m tilmanocept displays more rapid injection site clearance, high sentinel node extraction, and … It is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa dextran backbone [FDA Label].

  5. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.[L45643,L45818]. … It is produced by recombinant DNA technology using a mammalian cell expression system.

  6. Drug

    Anti-inhibitor coagulant complex

    go.drugbank.com/drugs/DB13151
    ApprovedInvestigational

    It is used to control bleeding in hemophilia A and B patients with inhibitors.

    Products: FEIBA 500 U, FEIBA 1000 U
  7. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … Coagulation Factor XIII A-Subunit (Recombinant), also known as catridecacog, is a recombinant form of the Factor XIII-A2 homodimer composed of two factor XIII (FXIII) A-subunits [FDA Label].

    Synonyms: Factor XIII A-Subunit (Recombinant), Coagulation Factor XIII A-Subunit (recombinant)
  8. Drug

    Aluminium

    go.drugbank.com/drugs/DB01370
    ApprovedInvestigationalWithdrawn

    A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.

    Synonyms: Al
  9. Drug

    Corifollitropin alfa

    go.drugbank.com/drugs/DB09066
    ApprovedInvestigational

    This drug used together with _a gonadotropin-releasing hormone (GnRH) antagonist_, a type of medicine also used in fertility treatments. Elonva is available only by prescription [L2270]. … Corifollitropin alfa is produced by a method known as ‘recombinant DNA technology’.

  10. Drug

    Drotrecogin alfa

    go.drugbank.com/drugs/DB00055
    ApprovedWithdrawn

    It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. … Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.